In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae

  title={In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae},
  author={R. Schaadt and B. Yagi and G. Zurenko},
  journal={Antimicrobial Agents and Chemotherapy},
  pages={371 - 372}
Cefpodoxime proxetil is an oral cephalosporin antibiotic. The in vitro activities of cefpodoxime (the active metabolite of cefpodoxime proxetil), ceftriaxone, and cefuroxime against both antibiotic-susceptible and antibiotic-resistant clinical isolates of Neisseria gonorrhoeae were determined. Cefpodoxime inhibited all penicillin-susceptible strains and penicillinase-producing strains at less than or equal to 0.015 microgram/ml; chromosomally resistant strains were inhibited by cefpodoxime at… Expand
Cefpodoxime proxetil: a comprehensive review.
  • W. Todd
  • Medicine
  • International journal of antimicrobial agents
  • 1994
Cefpodoxime proxetil, a relatively new broad-spectrum third-generaation cephalosporin, has very good in vitro activity against Enterobacteriaceae, Hemophilus spp. and Moraxella spp., includingExpand
Susceptibility of Neisseria gonorrhoeae to cefpodoxime: determination of MICs and disk diffusion zone diameters
Susceptibility measurements were consistent for disk diffusion zone diameter and MIC, with an overall agreement of 215 of 225 (96%) for ceftriaxone, penicillin, and tetracycline combined. Expand
Microbiological Evaluation of Cefpodoxime Proxetil
In vitro models simulating human serum cefpodoxime concentrations demonstrate that a dosage regimen of 200mg is probably sufficient to treat most infections, however, further study is needed to clarify whether infections due to bacteria such as S. aureus, with higher cef podoxime MICs, can be treated with this dose regimen. Expand
Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.
Oral third-generation cephalosporins, such as cefixime, appear to represent potentially useful clinical alternatives to parenteral drugs of the same class for single-dose therapy of gonorrhea. Expand
Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae.
Cefdinir, cefetamet, and cefpodoxime, three orally administered cephalosporins, were tested against 100 strains of Neisseria gonorrhoeae having various antimicrobial susceptibility patterns and ceferdinir was the most active compound (MIC90 micrograms/ml) especially against gonococci with chromosomal-mediated resistance to penicillin. Expand
Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.
  • T. Fekete
  • Medicine
  • Clinical Microbiology Reviews
  • 1993
Current technology has overcome many of the objections to AST for N. gonorrhoeae with standardization of test media and the development of an accurate disk diffusion AST method that is suited to most clinical laboratories regardless of volume or level of technical expertise. Expand
Cefpodoxime Proxetil
A convenient twice daily oral regimen of cefpodoxime proxetil can be prescribed as an effective alternative to established β-lactam therapies in the empirical outpatient treatment of infections of the respiratory and urinary tracts as well as those of the skin and soft tissues. Expand


In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.
Systemic infections in mice caused by various pathogens, including beta-lactamase-producing strains, responded well to therapy with oral doses of CS-807, a new oral prodrug of R-3746, a cephalosporin derivative, with potent in vitro and in vivo antibacterial activity against both gram-positive and gram-negative bacteria. Expand
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin
A new orally absorbed cephalosporin ester was not hydrolyzed by the common beta-lactamases present in many of the pathogens causing respiratory and urinary tract infections in outpatients and was more active than cephalexin against these bacteria. Expand
Studies on orally active cephalosporin esters.
3-Methoxymethyl cephem derivatives having a 2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamide function at C-7 showed good activity against a wide variety of bacteria including some beta-lactamase producing species. Expand
Susceptibility tests: agar dilution
  • Manual of clinical microbiology,
  • 1985
Kalamazoo County Department of Health), A. Erlandson (Bronson Methodist Hospital), and R. Rice (Neisseria Reference Laboratory) for providing the Neisseria isolates used in this study